In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Why California wants to stop 23andMe's sale to former CEO How a Peninsula company is brewing cheaper Narcan in the U.S. How a ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Prothena said it would reduce its workforce after a recent trial failed to meet its primary and secondary endpoints. The Irish biotechnology company is planning a "substantial" job cut as it aims ...

Prothena to receive $55 million from Bristol Myers Squibb for exclusive worldwide license to PRX005, building on exclusive U.S. license which was optioned in June 2021 ...

Prothena shares fell after the company reported unfavorable trial results and said it would shrink its workforce. The stock was down 27% to $4.81 in pre-market trading Tuesday. The Irish ...